Document:

Employee Stock Purchase Plan of the Company

 EXHIBIT 10.1 
 ORTHOVITA, INC. 
 EMPLOYEE STOCK PURCHASE PLAN 
 Amended and Restated as of June 26, 2008 

 ARTICLE I 
 Introduction 
 1.01 Statement of Purpose. The purpose of the Orthovita, Inc. Employee Stock Purchase
Plan (the “Plan”) is to provide eligible employees of Orthovita, Inc. (the “Company”) and its subsidiaries an opportunity to purchase common stock of the Company. The Board of Directors of the Company believes that employee
participation in stock ownership will be to the mutual benefit of both the employees and the Company. 
 1.02 Internal Revenue Code
Considerations. The Plan is intended to constitute an “employee stock purchase plan” within the meaning of section 423 of the Internal Revenue Code of 1986, as amended. 
 1.03 ERISA Considerations. The Plan is not intended and shall not be construed as constituting an “employee benefit plan,” within the
meaning of section 3(3) of the Employee Retirement Income Security Act of 1974, as amended. 
 ARTICLE II 
 Definitions 
 2.01 “Board of
Directors” means the board of directors of the Company or a committee of the board of directors authorized to act on its behalf. 
 2.02 “Code” means the Internal Revenue Code of 1986, as amended, and any successor statute of similar nature. References to specific sections of the Code shall be taken to be references to corresponding sections of any
successor statute. 
 2.03 “Committee” means the committee appointed by the Board of Directors to administer the Plan, as
provided in Section 6.03. 
 2.04 “Company” means Orthovita, Inc., a Pennsylvania corporation. 
 2.05 “Compensation” means all cash compensation (including, but limited to, salary, commissions and bonuses) received by an Employee
from the Company or a Subsidiary and includible in the Employee’s gross income for federal income tax purposes. 
 2.06
“Continuous Service” means the period of time immediately preceding the Election Date during which the Employee has been employed by an Employer and during which there has been no interruption of the Employee’s employment with
the Employer. For this purpose, periods of Excused Absence shall not be considered to be interruptions of Continuous Service. 
 2.07
“Effective Date” shall mean June 26, 2008, provided that the Plan is approved by the shareholders of the Company within twelve (12) months after the date on which the Plan is adopted. 
  

 2 

 2.08 “Election Date” means each January 1, April 1, July 1 and
October 1 or such other dates as the Committee shall specify. The first Election Date for the Plan shall be the Effective Date. 
 2.09
“Eligible Employee” means each employee of the Employer (i) who is classified by the Employer as a full or part-time employee (and not as an independent contractor), (ii) whose customary employment is for more than twenty
(20) hours per week and for more than six (6) months per year, (iii) who is not deemed for purposes of section 423(b)(3) of the Code to own stock possessing five percent (5%) or more of the total combined voting power or value of
all classes of stock of the Company or any subsidiary, and (iv) who has completed at least six (6) months of Continuous Service with the Employer. 
 2.10 “Employer” means the Company and each Subsidiary. 
 2.11 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and as the same may hereafter be amended. 
 2.12 “Excused
Absence” means absence pursuant to a leave of absence granted by the Employer, absence due to disability or illness, absence by reason of a layoff or inactive status due to completion of an assignment, or absence by reason of uniformed
service within the meaning of the Uniformed Services Employment and Reemployment Rights Act (“USERRA”). In no event may an Excused Absence exceed six (6) months in length (or, if longer and if applicable, the period of the
individual’s uniformed services within the meaning of the USERRA and such period thereafter as such individual’s right to reemployment by the Employer is protected by law), and any absence shall cease to be an Excused Absence upon the
earlier of (a) the last day of the calendar month in which the duration of the absence reaches six (6) months (or such longer period as may be required under the USERRA or other applicable law) or (b) the last day of the calendar
month in which the leave expires by its terms, the layoff or inactive status ends by recall or permanent separation from service, or recovery from illness or disability occurs. 
 2.13 “Market Value” means the last price for the Stock as reported on the principal market on which the Stock is traded for the date of
reference. If there was no such price reported for the date of reference, “Market Value” means the last reported price for the Stock on the day next preceding the date of reference for which such price was reported. 
 2.14 “Participant” means each Eligible Employee who elects to participate in the Plan. 
 2.15 “Plan” means the Orthovita, Inc. Employee Stock Purchase Plan, as set forth herein and as hereafter amended. 
 2.16 “Purchase Agreement” means the instrument prescribed by the Committee pursuant to which an Eligible Employee may enroll as a
Participant and subscribe for the purchase of shares of Stock on the terms and conditions offered by the Company. The Purchase Agreement is intended to evidence the Company’s offer of an option to the Eligible Employee to purchase Stock on the
terms and conditions set forth therein and herein. 
 2.17 “Purchase Date” means the last day of each Purchase Period.

  

 3 

 2.18 “Purchase Period” means each calendar quarter or other period specified by the
Committee, beginning on or after the Effective Date, during which the Participant’s Stock purchase is funded through payroll deduction accumulations. 
 2.19 “Purchase Price” means the purchase price for shares of Stock purchased under the Plan, determined as set forth in Section 4.03. 
 2.20 “Stock” means the common stock of the Company. 
 2.21 “Subsidiary” means any present or future corporation (i) which constitutes a “subsidiary corporation” of the Company as that term is defined in section 424 of the Code, and
(ii) is designated as a participating entity in the Plan by the Committee. Unless the Committee specifically designates otherwise, a Canadian or other foreign subsidiary shall not be considered a Subsidiary for purposes of the Plan, and
employees of such a subsidiary shall not be Eligible Employees. 
 ARTICLE III 
 Admission to Participation 
 3.01 Initial Participation. An Eligible Employee
may elect to participate in the Plan and may become a Participant effective as of any Election Date, by executing and filing with the Committee a Purchase Agreement at such time in advance of such Election Date as the Committee shall prescribe. The
Purchase Agreement shall remain in effect until modified or canceled in accordance with the terms of this Plan. 
 3.02 Discontinuance of
Participation. A Participant may voluntarily cease his or her participation in the Plan and stop payroll deductions at any time by filing a notice of cessation of participation on such form and at such time in advance of the effective date as
the Committee shall prescribe. Notwithstanding anything in the Plan to the contrary, if a Participant ceases to be an Eligible Employee, his or her participation automatically shall cease and no further purchase of Stock shall be made for the
Participant. 
 3.03 Readmission to Participation. Any Eligible Employee who has previously been a Participant, who has discontinued
participation (whether by cessation of eligibility or otherwise), and who wishes to be reinstated as a Participant may again become a Participant by executing and filing with the Committee a new Purchase Agreement. Reinstatement to Participant
status shall be effective as of any Election Date, provided the Participant files a new Purchase Agreement with the Committee at such time in advance of the Election Date as the Committee shall prescribe. 
 ARTICLE IV 
 Stock Purchase and Resale

 4.01 Reservation of Shares. There shall be 500,000 shares of Stock reserved for issuance or transfer under the Plan, subject to
adjustment in accordance with the antidilution provisions hereinafter set forth. Except as provided in Section 5.02, the aggregate number of shares of Stock that may be purchased under the Plan shall not exceed the number of shares of Stock
reserved under the Plan. 
  

 4 

 4.02 Limitation on Shares Available. The maximum number of shares of Stock that may be purchased
for each Participant on a Purchase Date is the lesser of (a) the number of whole and fractional shares of Stock that can be purchased by applying the full balance of the Participant’s withheld funds to the purchase of shares of Stock at
the Purchase Price, or (b) the Participant’s proportionate part of the maximum number of shares of Stock available under the Plan, as stated in Section 4.01. Notwithstanding the foregoing, if any person entitled to purchase shares
pursuant to any offering under the Plan would be deemed for purposes of section 423(b)(3) of the Code to own stock (including any number of shares of Stock that such person would be entitled to purchase hereunder) possessing five percent
(5%) or more of the total combined voting power or value of all classes of stock of the Company, the maximum number of shares of Stock that such person shall be entitled to purchase pursuant to the Plan shall be reduced to that number which,
when added to the number of shares of stock that such person is deemed to own (excluding any number of shares of Stock that such person would be entitled to purchase hereunder), is one less than such five percent (5%). Any amounts withheld from a
Participant’s Compensation that cannot be applied to the purchase of Stock by reason of the foregoing limitation shall be returned to the Participant as soon as practicable. 
 4.03 Purchase Price of Shares. The Purchase Price per share of the Stock sold to Participants pursuant to any offering under the Plan shall be
ninety-five percent (95%) of the Market Value of such share on the Purchase Date. Notwithstanding the foregoing, the Board of Directors may determine that the Purchase Price shall be the Market Value, or a percentage of the Market Value, on the
Purchase Date, so long as the percentage shall not be lower than ninety-five percent (95%) of such Market Value. 
 4.04 Exercise of
Purchase Privilege. 
 (a) Each Participant shall be granted an option to purchase shares of Stock as of the first day of each Purchase
Period at the Purchase Price specified in Section 4.03. The option shall continue in effect through the Purchase Date for the Purchase Period. Subject to the provisions of Section 4.02 above and of paragraph (c) of this
Section 4.04, on each Purchase Date, the Participant shall automatically be deemed to have exercised his or her option to purchase shares of Stock, unless he or she notifies the Committee, in such manner and at such time in advance of the
Purchase Date as the Committee shall prescribe, of his or her desire not to make such purchase. 
 (b) There shall be purchased for the
Participant on each Purchase Date, at the Purchase Price for the Purchase Period, the largest number of whole and fractional shares of Stock as can be purchased with the amounts withheld from the Participant’s Compensation during the Purchase
Period. Each such purchase shall be deemed to have occurred on the Purchase Date occurring at the close of the Purchase Period for which the purchase was made. 
 (c) A Participant may not purchase shares of Stock having an aggregate Market Value of more than twenty-five thousand dollars ($25,000), determined at the beginning of each Purchase Period, for any calendar year in
which one or more offerings under this Plan are outstanding at any time, and a Participant may not purchase a share of Stock under any offering after the expiration of the Purchase Period for the offering. 
  

 5 

 4.05 Payroll Deductions. Each Participant shall authorize payroll deductions from his or her
Compensation for the purpose of funding the purchase of Stock pursuant to his or her Purchase Agreement. In the Purchase Agreement, each Participant shall authorize an after-tax payroll deduction from each payment of Compensation during a Purchase
Period of an amount not less than $10 per paycheck ($20 for any Participant on a monthly payroll period) and not more than 10% of such Participant’s Compensation. A Participant may change the deduction to any permissible level effective as of
any Election Date. A change shall be made by the Participant’s filing with the Committee a notice in such form and at such time in advance of the date on which the change is to be effective as the Committee shall prescribe. 
 4.06 Payment for Stock. The Purchase Price for all shares of Stock purchased by a Participant under the Plan shall be paid out of the
Participant’s authorized payroll deductions. All funds received or held by the Company under the Plan are general assets of the Company, shall be held free of any trust or other restriction, and may be used for any corporate purpose.

 4.07 Share Ownership; Issuance of Certificates. 
 (a) The shares of Stock purchased by a Participant on a Purchase Date shall, for all purposes, be deemed to have been issued or sold at the close of business on the Purchase Date. Prior to that time, none of the
rights or privileges of a shareholder of the Company shall inure to the Participant with respect to such shares of Stock. All the shares of Stock purchased under the Plan shall be delivered by the Company in a manner as determined by the Committee.

 (b) The Committee, in its sole discretion, may determine that shares of Stock shall be delivered by the Company by (i) issuing and
delivering to the Participant a certificate for the number of shares of Stock purchased by the Participant on a Purchase Date or during a calendar year or other period determined by the Committee, (ii) issuing and delivering certificates for
the number of shares of Stock purchased by all Participants on a Purchase Date or during a calendar year or other period determined by the Committee to a firm which is a member of the National Association of Securities Dealers, as selected by the
Committee from time to time, which shares shall be maintained by such firm in a separate brokerage account for each Participant, or (iii) issuing and delivering certificates for the number of shares of Stock purchased by all Participants on a
Purchase Date or during the calendar year or other period determined by the Committee to a bank or trust company or affiliate thereof, as selected by the Committee from time to time, which shares may be held by such bank or trust company or
affiliate in street name, but with a separate account maintained by such entity for each Participant reflecting such Participant's share interests in the Stock. Each certificate or account, as the case may be, may be in the name of the Participant
or, if he or she so designates on the Participant’s Purchase Agreement, in the Participant's name jointly with the Participant’s spouse, with right of survivorship. A Participant who is a resident of a jurisdiction that does not recognize
such joint tenancy may have a certificate or account held in the Participant's name as tenant in common with the Participant’s spouse, with or without right of survivorship. 
 (c) In addition to any restrictions or limitations on the resale of Stock purchased under the Plan as set forth in Section 4.08 or otherwise
hereunder, the Committee, in its sole discretion, may impose such restrictions or limitations as it shall determine on the resale of Stock, the issuance of individual stock certificates or the withdrawal from any shareholder accounts established for
a Participant. 
  

 6 

 (d) Any dividends payable with respect to whole or fractional shares of Stock credited to a shareholder
account of a Participant established pursuant to Section 4.07(b) hereof will be reinvested in shares of Stock and credited to the Participant’s account. 
 4.08 Withdrawal of Shares or Resale of Stock. 
 (a) A Participant may request a withdrawal of shares
of Stock purchased for the Participant under the Plan or order the sale of such shares at any time by making a request in such form and at such time as the Committee shall prescribe. 
 (b) If a Participant terminates his or her employment with the Employer or otherwise ceases to be an Eligible Employee, the Participant shall receive a
distribution of his or her shares of Stock held in any shareholder account established pursuant to Section 4.07(b), unless the Participant elects to have the shares of Stock sold in accordance with such procedures as the Committee shall
prescribe. 
 (c) If a Participant is to receive a withdrawal or distribution of shares of Stock, or if shares are to be sold, the
withdrawal, distribution or sale shall be made in whole shares of Stock, with fractional shares paid in cash. 
 ARTICLE V 
 Special Adjustments 
 5.01 Shares
Unavailable. If, on any Purchase Date, the aggregate funds available for the purchase of Stock would purchase a number of shares in excess of the number of shares of Stock then available for purchase under the Plan, the following events shall
occur: 
 (a) The number of shares of Stock that would otherwise be purchased by each Participant shall be proportionately reduced on the
Purchase Date in order to eliminate such excess; and 
 (b) The Plan shall automatically terminate immediately after the Purchase Date as of
which the supply of available shares is exhausted. 
 5.02 Anti-Dilution Provisions. The aggregate number of shares of Stock reserved
for purchase under the Plan, as provided in Section 4.01, and the calculation of the Purchase Price per share may be appropriately adjusted to reflect any increase or decrease in the number of issued shares of Stock resulting from a subdivision
or consolidation of shares or other capital adjustment, or the payment of a stock dividend, or other increase or decrease in such shares, if effected without receipt of consideration by the Company. Any such adjustment shall be made by the Committee
acting with the consent of, and subject to the approval of, the Board of Directors. 
 5.03 Effect of Certain Transactions. Subject to
any required action by the shareholders, if the Company shall be the surviving corporation in any merger or consolidation, 

  

 7 

 
any offering hereunder shall pertain to and apply to the shares of stock of the Company. However, in the event of a dissolution or liquidation of the
Company, or of a merger or consolidation in which the Company is not the surviving corporation, the Plan and any offering hereunder shall terminate upon the effective date of such dissolution, liquidation, merger or consolidation, and the balance of
any amounts withheld from a Participant’s Compensation which had not by such time been applied to the purchase of Stock shall be returned to the Participant. 
 ARTICLE VI 
 Miscellaneous 
 6.01 Non-Alienation. The right to purchase shares of Stock under the Plan is personal to the Participant, is exercisable only by the Participant during the Participant’s lifetime, except as hereinafter set
forth, and may not be assigned or otherwise transferred by the Participant. If a Participant dies, there shall be delivered to the executor, administrator or other personal representative of the deceased Participant such shares of Stock and such
residual amounts as may remain to the Participant’s credit from amounts withheld from the Participant’s Compensation as of the Purchase Date occurring at the close of the period in which the Participant’s death occurs, including
shares of Stock purchased as of that date or prior thereto with moneys withheld from the Participant’s Compensation. 
 6.02
Administrative Costs. The Company shall pay all administrative expenses associated with the operation of the Plan. 
 6.03 The
Committee. The Board of Directors shall appoint a Committee, which shall have the authority and power to administer the Plan and to make, adopt, construe, and enforce rules and regulations not inconsistent with the provisions of the Plan. The
Committee shall adopt and prescribe the contents of all forms required in connection with the administration of the Plan, including, but not limited to, the Purchase Agreement, payroll withholding authorizations, withdrawal documents, and all other
notices required hereunder. The Committee shall have the fullest discretion permissible under law in the discharge of its duties. The Committee's interpretations and decisions with respect to the Plan shall be final and conclusive. 
 6.04 Amendment of the Plan. The Board of Directors may, at any time and from time to time, amend the Plan in any respect, except that no amendment
may (i) increase the number of shares reserved for purposes of the Plan, or (ii) allow any person who is not an Eligible Employee to become a Participant, without the approval of the shareholders of the Company. 
 6.05 Expiration and Termination of the Plan. The Plan shall continue in effect for ten (10) years from the Effective Date, unless terminated
prior to that date pursuant to the provisions of the Plan or pursuant to action by the Board of Directors. The Board of Directors shall have the right to terminate the Plan at any time without prior notice to any Participant and without liability to
any Participant. Upon the expiration or termination of the Plan, the balance, if any, then standing to the credit of each Participant from amounts withheld from the Participant's Compensation which has not, by such time, been applied to the purchase
of Stock shall be refunded to the Participant. 
  

 8 

 6.06 Repurchase of Stock. The Company shall not be required to purchase or repurchase from any
Participant any of the shares of Stock that the Participant acquires under the Plan. 
 6.07 Notice. A Purchase Agreement and any
notice that a Participant files pursuant to the Plan shall be on the form prescribed by the Committee and shall be effective only when received by the Committee. Delivery of such forms may he made by hand or by certified mail, sent postage prepaid,
to Orthovita, Inc. 77 Great Valley Parkway, Malvern, PA 19355, Attention: Employee Stock Purchase Plan Administrator. Delivery by any other mechanism shall be deemed effective at the option and discretion of the Committee. 
 6.08 Government Regulation. The Company’s obligation to sell and to deliver the Stock under the Plan is at all times subject to all approvals
of any governmental authority required in connection with the authorization, issuance, sale or delivery of such Stock. 
 6.09 Headings,
Captions, Gender. The headings and captions herein are for convenience of reference only and shall not be considered as part of the text. The masculine shall include the feminine, and vice versa. 
 6.10 Severability of Provisions, Prevailing Law. The provisions of the Plan shall be deemed severable. In the event any such provision is
determined to be unlawful or unenforceable by a court of competent jurisdiction or by reason of a change in an applicable statute, the Plan shall continue to exist as though such provision had never been included therein (or, in the case of a change
in an applicable statute, had been deleted as of the date of such change). The Plan shall be governed by the laws of the Commonwealth of Pennsylvania to the extent such laws are not in conflict with, or superseded by, federal law. 
  

 9Amendment No. 8 to Exclusive License Agreement and Letter Agreement

 EXHIBIT 10.1 
 AMENDMENT NO. 8 TO THE 
 PATENT AND TECHNOLOGY LICENSE AGREEMENT 
 This AMENDMENT NO. 8 (“AMENDMENT NO. 8”) to the ORIGINAL LICENSE (as defined below) effective this 4th
day of April, 2008 (“AMENDMENT NO. 8 EFFECTIVE DATE”) is made by and between the BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, a component institution of SYSTEM), and ARONEX
PHARMACEUTICALS, INC., a Delaware corporation having a principal place of business located at 3 Forbes Road, Lexington, Massachusetts 02421 (“LICENSEE”), a wholly-owned subsidiary of ANTIGENICS INC., a Delaware corporation. BOARD and
LICENSEE may be referred to hereafter collectively as the “PARTIES.” Capitalized terms not defined herein shall have the meaning set forth in the ORIGINAL LICENSE. 
 RECITALS 
  

	A.	BOARD and LICENSEE are parties to that certain Exclusive License Agreement dated effective as of July 1, 1988 (such Exclusive License Agreement, as previously amended from time
to time, the “ORIGINAL LICENSE”); 

  

	B.	BOARD and LICENSEE desire to amend the ORIGINAL AGREEMENT to, among other things, clarify AMENDMENT NO. 6 to the ORIGINAL LICENSE to correct a scrivener’s error and clarify the
rights of the PARTIES with respect to the Licensed Subject Matter, “Submicron Liposome Suspensions Obtained from Preliposome Lyophilizates.” 

 NOW, THEREFORE, in consideration of the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, the PARTIES hereby agree to the following: 
  

	1.	The Parties acknowledge and agree that the subject matter of the patent rights relating to MDA 94-031 CON1, U.S. Application No. 09/122,427, entitled “Submicron Liposome
Suspensions Obtained from Preliposome Lyophilizates” has and shall remain part of Schedule I, except as expressly set forth herein. 

  

	2.	The PARTIES further acknowledge and agree that, effective as of the AMENDMENT NO. 6 EFFECTIVE DATE, the specific patent right U.S. Patent No. 5,902,604 constituted RETURNED
TECHNOLOGY and was removed from Schedule 1. 

  

	3.	The PARTIES further acknowledge and agree that, to the extent it was not already included in the definition of “RETURNED TECHNOLOGY” in AMENDMENT NO. 6, on
January 16, 2007, LICENSEE returned to BOARD the specific patent right, EP 96918419.1 and all European applications claiming priority therefrom, and as of such date, such patent right constituted RETURNED TECHNOLOGY. 

	4.	For the avoidance of doubt, the PARTIES further acknowledge and agree that U.S. Patent Application No. 09/122,427, (MDA94-031 CON1), its foreign equivalents (excluding the
specific European patent rights identified in Paragraph 3 of this AMENDMENT NO. 8, above), and any divisionals, continuations, reissues, reexaminations or extensions thereof, and all patents and/or patent applications, domestic or foreign (excluding
the specific European patent rights identified in Paragraph 3 of this AMENDMENT NO. 8, above), which claim priority, directly or indirectly, to U.S. Patent Application No. 08/468,791, now U.S. Patent No. 5,902,604, including, but not
limited to, the foreign applications/patents listed below, do not constitute RETURNED TECHNOLOGY and have and shall remain Board Patent Rights licensed to LICENSEE under the ORIGINAL LICENSE, and that the subject matter of these patent rights have
and shall remain Licensed Subject Matter: 

  

							
	 Our Ref. No.
	  	 Country
	  	 Serial/Application No.
	  	 Filed

	 8449-238-001
	  	Canada	  	2,221,341	  	6/6/96
				
	 8449-238-007
	  	Australia	  	61087/96	  	6/6/96
				
	 8449-238-012
	  	Japan	  	9-502034	  	6/6/96

 Notwithstanding the foregoing, the Parties further acknowledge and agree that all of the patents
rights (including applications and issued patents) identified in this paragraph 4 are included within the definition of “Subject Patent” as defined in Section 11, page 6 to AMENDMENT NO. 6 and, effective as of the AMENDMENT NO. 6
EFFECTIVE DATE, all of the foregoing are included in the license granted by LICENSEE to BOARD in the Anthracycline Field as set forth in Section 11, page 6 of AMENDMENT NO. 6. For purposes of clarification, and not by way of limitation, U.S.
Patent No. 5,902,604, is not within the definition of “Subject Patent,” but is and remains RETURNED TECHNOLOGY. 
  

	5.	The PARTIES acknowledge and agree that, except as set forth in this AMENDMENT NO. 8, the terms and conditions of the ORIGINAL LICENSE shall remain in full force and effect.

  

	6.	This AMENDMENT NO. 8 may be executed by the PARTIES hereto in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts
shall together constitute one and the same instrument. Each counterpart may consist of a number of copies hereof each signed by less than all, but together signed by all of the PARTIES hereto. 

 IN WITNESS WHEREOF, the PARTIES hereto have caused their duly authorized representatives to execute this AMENDMENT NO. 8
as of the AMENDMENT NO. 8 EFFECTIVE DATE. 
  

							
	THE UNIVERSITY OF TEXAS	 	THE BOARD OF REGENTS OF
	M. D. ANDERSON CANCER CENTER	 	UNIVERSITY OF TEXAS SYSTEM
				
	By:	 	 /s/ Leon Leach
	 	By:	 	 /s/ John Mendelsohn

		 	Leon Leach	 		 	John Mendelsohn, M.D.
		 	Executive Vice President	 		 	President
		 	M. D. Anderson Cancer Center	 		 	M. D. Anderson Cancer Center
		
	Date: 4/3/08	 	Date: 4/4/08

 APPROVED AS TO CONTENT: 
  

			
	By:	 	 /s/ Christopher C. Capelli

		 	Christopher C. Capelli, MD
		 	VP, Technology Based Ventures
		 	Office of Technology Commercialization
		 	M. D. Anderson Cancer Center
	
	Date: 10/16/07

  

			
	ARONEX PHARMACEUTICALS, INC.:
		
	By:	 	 /s/ Deanna M. Petersen

	Name:	 	Deanna M. Petersen
	Title:	 	Vice President
	
	Date: October 11, 2007

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]